课题基金 / 基金详情

Investigating patient immune reponse as a biomarker and theraputic target advanced prostate cancer

Investigating patient immune reponse as a biomarker and theraputic target advanced prostate cancer
研究患者免疫反应作为晚期前列腺癌的生物标志物和治疗目标
批准号：
411306
负责人：
Wang Hanzhi
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-12-01 至 2019-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=411306&lang=en
关键词：
Brachytherapy External Beam Radiation Immune Response Patient Samples Pd-L1 Prostate Cancer Radiation Syngeneic Mouse Model

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
High grade prostate cancer (PCa) patients are at risk of developing metastases despite radiotherapy. A study found that patients treated with brachytherapy (BT) and EBRT (external beam radiotherapy) had a lower rate of metastases compared to EBRT alone1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金